Soleno Therapeutics, Inc.
SLNO
$48.12
-$0.91-1.85%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 76.83% | 436.92% | 563.11% | 685.26% | 519.08% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 32.12% | 219.70% | 281.03% | 376.93% | 332.00% |
| Operating Income | 39.14% | -172.03% | -281.03% | -376.93% | -332.00% |
| Income Before Tax | 40.19% | -176.84% | -280.98% | -351.04% | -295.33% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 40.19% | -176.84% | -280.98% | -351.04% | -295.33% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 40.19% | -176.84% | -280.98% | -351.04% | -295.33% |
| EBIT | 39.14% | -172.03% | -281.03% | -376.93% | -332.00% |
| EBITDA | 39.74% | -177.03% | -291.60% | -396.95% | -353.54% |
| EPS Basic | 44.85% | -70.28% | -72.18% | -43.20% | -2.66% |
| Normalized Basic EPS | 46.30% | -78.34% | -77.89% | -49.62% | -2.14% |
| EPS Diluted | 44.32% | -70.30% | -72.20% | -43.22% | -2.67% |
| Normalized Diluted EPS | 45.85% | -78.34% | -77.89% | -49.62% | -2.14% |
| Average Basic Shares Outstanding | 28.28% | 51.15% | 84.43% | 144.33% | 270.96% |
| Average Diluted Shares Outstanding | 29.34% | 51.15% | 84.43% | 144.33% | 270.96% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |